Issue 07 — Editorial
Evidence before hype.
A quiet, independent reading room for people who want the mechanism, the method and the caveats — not the marketing.
Latest articles
18 articles
Research · 5 September 2026 · 11 min read
BPC-157: What the Preclinical Evidence Shows and Why No Human Trial Data Exists
BPC-157 is one of the most discussed research peptides online, built almost entirely on animal studies from a single research group. A careful reading of what is published, what regulators have said, and what remains unproven.
Read
Research · 5 September 2026 · 12 min read
Growth Hormone Secretagogues: One Approved Drug, Several Research Compounds, and the Difference
Tesamorelin is an FDA-approved medicine with phase 3 trial data. Ipamorelin and sermorelin are not approved for general use and rest on far thinner evidence. What separates a licensed GHRH analogue from an online 'GH peptide'.
Research · 5 September 2026 · 10 min read
Semaglutide vs Tirzepatide: What the Head-to-Head Trial Evidence Actually Shows
Two approved incretin medicines, one direct comparison trial and a great deal of confusion in between. A source-checked reading of STEP 1, SURMOUNT-1, SURPASS-2 and the open-label SURMOUNT-5 comparison.
Research · 31 August 2026 · 6 min read
Investigational Peptides and Nociceptive Pathways: A Desk Review of Preclinical Candidates
An editorial evaluation of preclinical peptide compounds targeting inflammatory signaling, tissue regeneration, and neuropathic pathways in chronic pain research.
Research · 31 August 2026 · 5 min read
Pharmacokinetic Dynamics: Evaluating Delivery Routes and Systemic Bioavailability in Research
An analysis of how administration routes—from parenteral injections to mucosal and oral vectors—impact systemic exposure, metabolic degradation, and pharmacokinetic outcomes in experimental models.
Research · 31 August 2026 · 5 min read
Evaluating Mod GRF 1-29 (CJC-1295 Without DAC): Secretagogue Kinetics, Receptor Dynamics, and Experimental Limitations
An editorial review examining the short-acting GHRH analog Mod GRF 1-29 (CJC-1295 no DAC), its physiological mechanism, pulsatile release profiles, and comparative distinction from long-acting formulations.
Research · 31 August 2026 · 5 min read
Navigating Regulatory Boundaries: The Analytical and Regulatory Realities of 'Research Use Only' Peptides
An editorial examination of the 'Research Use Only' (RUO) designation in peptide science, detailing regulatory frameworks, analytical quality metrics, and the critical distinction between laboratory reagents and clinical preparations.
Research · 31 August 2026 · 6 min read
Metabolic Approaches to Respiratory Health: Evaluating GLP-1 Agonism in Obstructive Sleep Apnea
Public discussions surrounding high-profile athletes like Shaquille O'Neal highlight an emerging clinical intersection: how GLP-1 receptor agonists influence obstructive sleep apnea through systemic metabolic remodeling.
Research · 31 August 2026 · 6 min read
Evaluating GLP-1 Receptor Agonism and Cancer Risk: Metabolic and Direct Molecular Pathways
An inquiry into how glucagon-like peptide-1 receptor agonists influence oncological outcomes, distinguishing indirect metabolic improvements from cell-signaling anti-tumor mechanisms.
Research · 31 August 2026 · 5 min read
Deconstructing the KLOW Protocol: An Analytical Desk Review of Multi-Peptide Stacking
A rigorous examination of the speculative KLOW protocol, evaluating preclinical evidence for KPV, LL-37, BPC-157, and GHK-Cu against regulatory standards, athletic anti-doping rules, and analytical safety.
Research · 31 August 2026 · 14 min read
What Is Retatrutide? Mechanism, Phase 3 Results and Approval Status
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist at the GIP, GLP-1 and glucagon receptors. What the peer-reviewed trials show, how the 2026 topline Phase 3 results should be read, and why it is approved nowhere.
Research · 31 August 2026 · 6 min read
KPV in Preclinical Anti-Inflammatory Research: Mechanistic Insights and Mucosal Signaling
An investigation into Lysine-Proline-Valine (KPV), an alpha-MSH-derived tripeptide. We analyze its molecular targets, NF-κB modulation, and application in gut and cutaneous model systems.
Research · 31 August 2026 · 5 min read
BPC-157 in 2026: Evaluating the Preclinical Evidence, Regulatory Position, and the Human Data Gap
An editorial review of Body Protection Compound-157, examining preclinical tissue repair mechanisms, the absence of robust human trial data, anti-doping prohibitions, and evolving regulatory classifications.